Skip to content
Saturday, November 14, 2026
Capital Collective

Zimbabwe Rejects ‘Lopsided’ US Health Aid Deal Because of Information Concerns

Health funding image
The proposed US financial assistance was aimed at programmes for treating and preventing HIV/Aids, TB, and malarial diseases.

Zimbabwe has rejected a major American healthcare agreement valued at 367 million US dollars (£272m) over five years due to the United States' insistence on sensitive biological samples.

This move became public following a official document from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "lopsided".

A government spokesperson later stated that the US was seeking genetic material for scientific study and commercial gain but refused to share the resulting advantages from future vaccines.

"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.

The US Embassy said the United States had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.

A physicians' group in Zimbabwe has urged further dialogue to secure a deal acceptable to all parties so the nation's critical HIV treatment initiative can be sustained.

Broader Background

Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a high court halted a similar health funding agreement after legal challenges were filed about the safety of citizens' medical information.

Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.

The agency had managed assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to enhance openness and accountability.

As per statements, Sixteen nations in Africa have so far agreed to these new agreements, representing over $18.3bn in new funding.

Specifics of the Rejected Deal

The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.

"It is our view this collaboration would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving HIV treatment through US-supported initiatives," the Ambassador commented.

However, official spokesman Nick Mangwana argued the proposed deal was "unequal".

"Our nation was requested to provide its biological resources and data over an extended period, without any equivalent guarantee of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," his statement read.

"Effectively, our country would supply the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our population if a new pandemic emerge."

Sovereignty and International Frameworks

Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were undermining systems already established through the global health agency.

The spokesperson cited its Pandemic Benefit-Sharing framework created to manage potential pandemics.

"This system is designed to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."

Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," he added.

"We are open to continued dialogue with our American counterparts on how future collaboration could be structured in a manner that honours the sovereignty and dignity of each country."

Medical Community Response

The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but recommended that negotiations should continue given that a large portion of the nation's HIV programmes were funded by external financing.

"If specific concerns arise, such as those involving information security or implementation frameworks, these can frequently be addressed through detailed discussion and mutually agreed protections," the group commented.

This impasse underscores the continuing challenges between accepting much-needed foreign assistance and safeguarding a country's data in an increasingly data-driven world.

KI
About the author

Kimberly Irwin

A London-based entrepreneur with over 15 years in fintech and startup consulting.

Capital Collective

Type to search articles.